To minimize risk to its newly cleaned manufacturing plant and to ensure that new supplies of the Gaucher-disease treatment Cerezyme will be available by the end of this year, Genzyme is discarding some 80 percent of the remaining in-process material. "We could not take the risk of processing material that has any possibility of re-contaminating the plant and setting back our ability to supply Cerezyme," says CEO Henri Termeer, in a statement. The company expects to begin releasing new material in November. Release